FDA, Medicare to join in plan

Improved safety of drugs, cutting waste are goals

May 23, 2008|By Ricardo Alonso-Zaldivar | Ricardo Alonso-Zaldivar,LOS ANGELES TIMES

WASHINGTON - Two government health agencies that have traditionally operated as self-contained bureaucratic fiefdoms announced yesterday a joint venture that promises to improve prescription drug safety for Americans, while potentially reducing wasteful spending on medications.

The Food and Drug Administration and Medicare agreed on rules for using information from Medicare's giant claims databases to create a computerized early-warning network for problems with medications and medical devices that come to light after they go on the market.

While Medicare will not turn over individual patient data to the FDA, the two agencies' computers will now be able to talk to each other, in effect, to pose and answer questions that may reveal potentially risky side effects in new drugs. Since pre-market testing usually involves a limited number of patients, serious problems sometimes become evident only after hundreds of thousands of people begin using a product.

The new system is called the Sentinel Initiative, and it will eventually include private insurers as well - to fill in information gaps about drugs that elderly don't use, such as contraceptives.

The FDA's current early warning system is nowhere near as comprehensive as the new system is expected to be. It relies on self-reporting by drugmakers, hospitals and doctors, and is believed to capture only between 1 percent and 10 percent of problems. Since the elderly are the major consumers of medications, Medicare's trove of inpatient, outpatient and prescription plan data is considered particularly rich.

Health and Human Services Secretary Michael O. Leavitt compared the FDA's current safety system to "looking at the stars from your backyard with the naked eye." The new system will provide a precise telescope, he added, and "you will see the stars trying to send you messages."

Setting up the network will not entail any major new expense for technology, officials said. Instead, the main task involves getting data experts from both agencies to work together under a mutually agreed on framework.

Sentinel could save taxpayers' money, said Medicare Administrator Kerry Weems, noting estimates that the cost of treating preventable drug reactions in the elderly is as high as $900 million a year.

"Our understanding of how well drugs work and how safe they are for the elderly or disabled has been limited," Weems said. "Clinical trials often exclude the very old, patients with multiple chronic conditions, and those taking multiple medications. Those cohorts comprise the vast majority of Medicare beneficiaries."

While collaboration between the FDA and Medicare sounds simple, it has taken years to bring this plan to fruition. The concept got a major push earlier in the Bush administration from Mark McClellan, who served first as FDA commissioner and later as Medicare administrator. Congress incorporated it in drug safety legislation passed last year.

The new system could shorten the time it takes to detect drug safety problems from years to months, McClellan said in an interview.

"What will be possible with this broader framework will be much larger scale analysis," he said. "It has the promise to detect potential problems far more quickly, and you can also learn about risks to particular groups of patients."

There has been little criticism of the new approach so far. However, privacy advocates are expected to give close scrutiny to the rules for information sharing between Medicare and the FDA, which will take effect in 30 days.

And drug companies have expressed some concerns, arguing that studies of large populations of patients in the real world are not as precise as controlled clinical trials, and could generate false alarms.

Janet Woodcock, who heads the FDA center that reviews new drugs, acknowledged that possibility - but said the alternative is worse.

"We completely understand and agree that getting information in this way isn't as free of bias as what we get in a clinical trial," she said. "However, in most cases, we don't have any way of getting this information at all right now."

The FDA is working on standards for interpreting data, and Woodcock said she hoped that would reduce chances of false alarms.

One of the major uses of the Sentinel network will be to address lingering doubts about new medications, Woodcock said.

For example, if pre-approval clinical trials had raised suspicion that a new drug might pose a particular kind of risk but not enough information could be gleaned from the trials to resolve the question with any kind of certainty.

In such a case, Woodcock said, FDA would query the Medicare databases to see if patients who took the medication had bad reactions. The FDA would get statistical answers, but no information on individual patients. However, public health agencies have authority under other federal laws to obtain private information in an investigation.

Ricardo Alonso-Zaldivar writes for the Los Angeles Times.

Baltimore Sun Articles
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.